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Abstract
Background: Microbes are associated with many human diseases and influence
drug efficacy. Small-molecule drugs may revolutionize biomedicine by fine-tuning the
microbiota on the basis of individual patient microbiome signatures. However, emerging endeavors in small-molecule microbiome drug discovery continue to follow a
conventional “one-drug-one-target-one-disease” process. A systematic pharmacology
approach that would suppress multiple interacting pathogenic species in the microbiome, could offer an attractive alternative solution.
Results: We construct a disease-centric signed microbe–microbe interaction network
using curated microbe metabolite information and their effects on host. We develop
a Signed Random Walk with Restart algorithm for the accurate prediction of effect of
microbes on human health and diseases. With a survey on the druggable and evolutionary space of microbe proteins, we find that 8–10% of them can be targeted by
existing drugs or drug-like chemicals and that 25% of them have homologs to human
proteins. We demonstrate that drugs for diabetes can be the lead compounds for
development of microbiota-targeted therapeutics. We further show that the potential
drug targets that specifically exist in pathogenic microbes are periplasmic and cellular
outer membrane proteins.
Conclusion: The systematic studies of the polypharmacological landscape of the
microbiome network may open a new avenue for the small-molecule drug discovery
of the microbiome. We believe that the application of systematic method on the polypharmacological investigation could lead to the discovery of novel drug therapies.
Keywords: Microbe–microbe interaction network, Polypharmacology, Drug discovery,
Systematical biology

Background
As the most abundant organism, symbiotic microbiome biomasses in human body
sites are as rich as the human somatic cells [1]. Traditional culture-based or non-culture-based methods only detect limited groups of microbes, restricting our scopes on
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a comprehensive understanding of the entire microbial community. Advances in high
throughput sequencing technology substantially enhance our powers to characterize the
microbial community. Up to date, thousands of microbe genomes have been sequenced
[2]. These large scale sequencing data collected have driven forward a myriad of intriguing researches, including finding microbiome biomarkers [3, 4], investigating their association with diseases [5, 6], and uncovering the dynamicity of microbial community [7,
8].
Small-molecule drugs offer new opportunities and has emerged as a new frontier for
microbiome drug discovery and precision medicine [9]. It has been shown that small
molecule drugs, like antibiotics, relieve bacterial infection symptoms by controlling the
overgrowth of pathogens [10]. However, many microbe species have developed drug
resistance mechanism, especially to several widely used antibiotics [11, 12]. This raises
the requirement for the investigation and discovery of new drugs. The second concern
that comes with drug intervention treatment is their adverse effect on other microbes,
non-pathogenic species or even probiotics [13, 14]. Drug intervention causes microbiota
compositional change. The current view believes that microbiota homeostasis is a crucial
healthy feature of our "forgotten organ" [15]. Elimination or diminution of healthy commensal microbes draws dysbiosis in our body site ecologically, and pathogenic microbes
take this advantage to causes symptoms like diarrhea and nausea [13]. Besides, the dysbiosis is found to associated with many diseases, including obesity [16], allergy [17], type
1 diabetes (T1D) [18] and type 2 diabetes(T2D) [19], inflammatory bowel disease (IBD)
[20], rheumatoid arthritis (RA) [21], autism [22] and cancer [23]. For instance, T1D
studies have shown that the abundance of Bacteroides in patient group is higher than
that in the control group [18]. Thus drugs minimizing side effects on other symbiotic
microbes are desired.
Emerging endeavors in small-molecule microbiome drug discovery continue to follow
a conventional “one-drug-one-target-one-disease” process. It is often insufficient and
less successful in tackling complex systematic diseases. Systems pharmacology, which
aims to modulate multiple microbe targets in the microbiome-microbiome interaction
network, could be a potentially powerful approach for microbiome drug discovery that
can solve the aforementioned concerns. There are many data-driven methods and textmining-based approaches to construct a microbe–microbe network based on existing
evidence. For data-driven methods, the networks were inferred based on microbiome
co-occurrence in the host [24, 25] or dynamic changes in a time course [26, 27]. However, these methods still suffer many issues, such as the challenge to get comparable
absolute microbe abundance [28, 29], the difficulty in biological interpretation and the
requirement of optimization of sampling strategies [30, 31]. Another popular approach
for constructing the microbe–microbe association network is through automatic textmining [32, 33]. These methods are error-prone, biased, and lack biological representation of complexed microbiome-microbiome associations such as competition and
corporation.
Microbiome network can also be reconstructed by knowledge-driven approaches.
Within these methods, network reconstruction is based on knowledge of curated
metabolites and biochemical reactions. In one study, a global interspecies metabolite
interaction network, NJS16, is constructed using microbe metabolites consumption
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and production information and it elucidates the interplay between different species in
human gut [34]. This network is used as the foundation for building a context-specific
network, MIN, which models growth rate effect by other species or microbiome community under certain conditions [34, 35]. NJS16 has also been applied in the construction of a multi-level trophic model of gut microbiome, which is used to simulate the
metabolites flows across microbes [36].
Here we constructed a disease-centric gut microbial community network to model
microbes and microbial community effects on host health. By inferring the microbe–
microbe relationship from their metabolites input and output profiles collected from
aforementioned genome-scale metabolic modeling [34], we simulate the propagating
process of microbe effect on host health using a new Signed Random Walk with Restart
algorithm (SRWR) [37]. We annotated 104 microbe nodes in the network based on their
effects on host health by manually literature review. To our knowledge, it is the first time
to integrate the effect of the microbiome on host health into a microbiome-microbiome
interaction network model. Additionally, our network represents mechanistic relationships between microbiomes and encodes them by positive or negative signed edges. By
contrast, all existing networks have only a single positive-signed edge and cannot model
complex interactions between microbiomes. This unique node-labeled signed network
model enabled us to predict the physiological roles of 409 unannotated microbes in the
network as potential pathogenic or commensal using SRWR [37]. It is noted that conventional Random Walk with Restart (RWR) and other state-of-the-art methods such as
Graph Neural Network [38–40] only work on networks with positive-weighted edges.
Because our network has also negative-weighted edges, a method that can model the
signed network such as SRWR is needed. Moreover, we need to predict complex label
propagations such as friend-of-enemy or enemy-of-enemy to determine if an unannotated microbiome is pathogenic or commensal. SRWR is designed to support this type of
analysis, and more powerful than Signed spectral Ranking (SR) [41] and Modified PageRank (MPR) [42].
In order to realize systems pharmacology of microbiome, many unanswered questions remain: what the chemical space is in which the chemical compounds will inhibit
pathogenic microbiome interactions but not disturb commensal microbiome? if we can
target multiple pathogenic microbiomes, at the same time not inhibit commensal microbiomes? To address these questions, we performed a survey on current knowledge of
drugs-targets interactions and found a significant number of genes that could potentially
be drug targets in each microbe based on sequence homology. Our analyses suggested
that a large number of genes have homologs to existing drug targets. We also identified
a list of potential protein targets specific to the pathogenic microbe and not to the commensal microbe. Our analyses considered how microbiome interplays with each other
at the metabolites level and how drugs affect microbe growth through genome analysis.
This application is not limited to the exemplar analysis performed here. The systematic
studies of polypharmacological landscape of microbiome network may open a new avenue for the small molecule drug discovery of microbiome.
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Results
A novel disease‑centric microbe–microbe interaction network

We here proposed a new microbe–microbe interaction network, which is inferred
from each microbe’s metabolite consumption and production profile. Microbes affect
each other through different mechanisms. (1) They have negative effects on each other
through competing for the same metabolite resources (Fig. 1A). (2) One microbe can
have positive effects on others through cross-feeding (Fig. 1A). (3) They can affect other
microbes positively or negatively by alternating their living environment, like the change
of pH. (4) They could also form predator–prey relationships. We characterize the first
two relationships between microbes through inferring an interaction network using
microbes’ metabolite consumption and production profiles (Fig. 1B). To be specific, the
extent of negative relationship is calculated as the Jaccard similarity of two microbe’s
metabolite consumption profiles (Fig. 2A). Intuitively, the more metabolites two
microbes consume in common, the higher the negative effect they have on each other.
On the other side, the positive effect is due to the cross-feeding relationship. The extent
of positive effect is calculated as the Jaccard similarity of one microbe’s production profile and the other’s consumption profile (Fig. 2B). It is worth mentioning that the positive
relationship between the two microbes is not symmetrical. Finally, the extents of positive
effect and negative effect are summarized to generate the final edge weights.
The microbe’s metabolite consumption and production profiles were curated elsewhere [34]. We include 513 microbe nodes in our network analysis (Fig. 3A and B).
These 513 nodes form strongly connected component in the network. This network has
the following merits: (1) The graph can thoroughly represent various types of microbe–
microbe relationships because the graph is directed. The relationships are not limited to
competition (++) and mutualism (−−), where microbes can positively affect each other
and negatively affect each other in both directions (Fig. 3C). “ + ” or “−” indicates that
the microbe has a positive or negative effect on the other in one direction, respectively. It
can also represent more diverse relationships, including the commensalism (+ 0), parasitism (+ −) and amenalism (− 0). 0 here indicates that no relationship is found in a
specific direction. (2) It is biologically meaningful and straightforward to interpret. (3)
This microbe–microbe interaction network can avoid the problem in the construction
of microbiome network based on the abundance correlation of microbiomes, such that
the correlation is sensitive to the data compositionality and is affected by low-abundance
[43, 44]. (4) It can be integrated with additional networks that are derived from other
information (e.g., environmental factors) into a more sophisticated heterogeneous network analysis framework.
As the "forgotten organ" of the human body, the microbiome can help to digest dietary macromolecules in gut [45], protect against many common infections [46, 47]
and maintain human health. On the other hand, infection of pathogenic species can
cause severe disorders or diseases. The diverse effects of microbes on human health
make it challenging to analyze and predict the impact of the whole microbiome ecosystem on human health. Many studies have shown that network analysis can effectively model the relationship and interplay between different species in microbiome
[48]. These interactions are usually represented by the edges connecting two microbe
nodes. A weight is assigned to denote the association extent and type. However,
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Fig. 1 Illustration of relationships between microbiomes. (A) Microbe A and B compete for metabolite a and
has a negative effect on each other. This negative relationship is shown with a red arrow. Microbe A and
microbe C have a cross-feeding relationship. Microbe A can degrade macromolecule a into metabolite c,
which can be taken by microbe C. Cross-feedings also exist between microbe B and C, and between
microbe B and D through metabolite c and d, respectively. (B) An example for the calculation of the
relationship between two microbes. Negative effects are calculated as the Jaccard similarity between
microbe’s consumption profiles. The positive effect is calculated as the Jaccard similarity of one microbe’s
consumption profile and another’s production profile. The final effect is the aggregation of the negative
effect and the positive effect

to our knowledge, these networks haven’t included information about the effect of
microbes on health. The network that combines the information of both microbe–
microbe interaction and microbe effect on health should be used for analyzing the
influence of microbiome ecosystem on host health. We manually curated the microbe
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Fig. 2 The Jaccard similarity among microbes’ metabolite consumption and production profiles. A microbe–
microbe negative effect score matrix computed as the Jaccard similarity of their metabolite consumption
profiles. B microbe–microbe positive effect score matrix computed as the Jaccard similarity of one
microbiome’s metabolite consumption profile and another’s metabolite production profile

function on host health through the literature review. Out of 513 microbes in our network, we curated 72 microbes having pathogenic effects, either as a cause of disease
or a contributor of human illness, and 32 microbes having commensal effects, helping
macro-molecules digestion or preventing from infections (Additional files 2 and 3).
Majority of microbes are still understudied, so their influences on human health are
not determined due to either lack of evidence or ambiguous descriptions. Some species have different strains which have different influence on human health [49]. The
manually curated information about microbe effects on human health is then added
in the network as the microbe node attributes. The commensal microbe nodes have
node weighted as " + 1", while the pathogenic microbe nodes have node weighted as
"-1". Other nodes that are left unlabeled are then annotated with a predicted value
using the known microbe nodes attribute and microbe–microbe interaction edge
information with a Signed Random Walk with Restart algorithm.

Microbe effect annotation with Signed Random Walk with Restart

Because many microbe effects on human health are unknown, we developed a graph
mining strategy to infer their effects based on annotated network. Using a Signed Random Walk with Restart (SRWR) model, each unannotated microbial species was treated
as a node with an unknown health effect attribute, and tested for how it was influenced
by the neighboring nodes in the network through corporation (positive signed edge)
and competition (negative signed edge). The advantage of incorporating SRWR model
into our analysis was on the fact that the network recognizes both cooperative relationships as well as the competitive relationships, which resembles the true nature of the
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Fig. 3 Illustration of Microbe–microbe network. A Negative relationships (red edges) between microbes.
Only the edges with weight lower than − 0.7 are shown for simplicity. B Positive relationships (green
edges) between microbes. Only the edges with a weight higher than 0.5 are shown for simplicity. C 5
relationships between microbes, competition (–), mutualism (+ +), commensalism(+ 0), parasitism (+ −) and
amenalism(− 0) are shown. −, + and 0 denotes a negative effect, a positive effect, and no effect, respectively.
pathogenic and commensal microbes curated through literature review are labeled in red and green,
respectively. Other microbes are labeled in gray

microbial ecology. The premise of our analysis is that “friend” of “friend” or “enemy” of
“enemy” will be “friend”, and “friend” of “enemy” or “enemy” of “friend” will be “enemy”.
To assess the accuracy of our predictions, we use the curated data set of the 32
commensal and 72 potential pathogenic bacterial species that affects human health
as a benchmark. Using leave-one-out cross-validation, we obtained confusion matrix
with an average F1 score of 0.905. Specifically, the prediction of positive nodes yielded
the precision of 0.780 and the recall of 1.000, while the prediction of negative nodes
yielded the precision of 1.000 and the recall of 0.875. This accurate SRWR algorithm
yielded the prediction of 135 positive nodes (potentially commensal) and 274 negative
nodes (potentially pathogenic) for 409 total species without annotations associated
with human health (Additional file 4).
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Survey on microbe protein druggability and structural predictability

A microbe protein is denoted druggable if drugs or drug-like chemicals can target this
protein or its homologs (i.e. proteins in the same gene family) [50]. To have a comprehensive view of drug targets space of the microbiome, we included all protein sequences
of microbe species collected by the Human Microbiome Project (HMP) in our study [2,
51]. Drugbank and ChEMBL databases are two of the most popular and updated drugtarget interaction databases [52, 53]. Up to date, DrugBank and ChEMBL possessed
more than 5000 and 15,500 protein target sequences and drug information interacting with these targets. We screened for the homologs of all protein sequences of each
microbe species in the target sequences set of each drug-target interaction database
using PSI-Blast[54–56]. The e-value resulting from a specific sequence search indicates
the number of hits we can get by chance when we search a protein sequence against
a database. From the plot of the percentage of protein with homologs in each microbe
versus −log (e-value), we determined that the elbow point of curve is at which e-value
is around 10e−60 (Fig. 4A). With this e-value as the threshold, we determined that 10%
and 8% of microbe protein sequences were found to have close homologs in DrugBank
and ChEMBL targets database. Besides, the structure information of protein is critical
for the structure-based drug design and polypharmacology [57]. The protein structures

Fig. 4 Percentage of protein targets in microbiomes that have sequence homologs in different databases, A
ChEMBL and Drugbank, and B PDB. E-value is the criterion used in the sequence similarity search by BLAST.
The lower e-value is, the closer homolog is
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saved in Protein Data Bank archive (PDB) are widely used for protein structure prediction, so we searches for the homologs, which show high sequence similarities with
microbe proteins, in PDB [58]. With e-value at 10e-60, we show that 25% of microbe
proteins have close homologs in PDB (Fig. 4B).

Drug repurposing analysis shows that drugs for Diabetes have potential to regulate
microbiomes

A successful treatment for human diseases caused by microbe infection is antibiotic
intervention, which is used to control the overgrowth of one or a group of pathogenic
microbes. Due to the overuse of them, many microbes have shown antibiotic resistance [11]. Another problem with some existing drugs is side effects on other symbiotic microbe species, which causes microbiome dysbiosis. Thus, disrupting pathogen
interaction network by targeting multiple pathogenic microbiomes but not disturbing
commensal microbiomes will be a potential powerful strategy for microbiome drug discovery. Because drug repurposing exhibits more advantages than developing a novel
drug [59], we perform a computational screen on FDA approved or investigational drugs
for innovative potential drugs for targeting microbes. To avoid undesirable side effects,
the drugs should not affect commensal microbes proteins. With this intuition, we search
for drugs that can potentially affect simultaneously multiple pathogenic microbes and
avoid undesirable effect on commensal microbes.
We performed the screening on two databases: Drugbank and STITCH. Most chemicals in the Drugbank database are drugs that are FDA approved or under investigation,
and most of the drug-target interactions have experimental evidence. We collected the
drugs that could target proteins that are homologs of proteins in 72 pathogenic microbes
and then excluded those targeting on homologs of proteins in 32 commensal microbes.
Ultimately, we found 589 drugs that satisfy this constraint (Additional file 5). On the
other side, parts of compounds in STITCH are predicted drugs that lack experimental
support. STITCH database also possesses predicted drug-targets interaction for each
microbe species. Thus the screen includes both drugs and some non-drug compounds.
Drug-target interactions in the STITCH database have various types, like inhibition,
activation, and catalysis. We conducted more specific screening by considering each
interaction type, as described in Methods. On average, one third of compounds in the
STITCH database are found to have pharmaceutical usage. Finally, we found 170 drugs
that appear in both STITCH screen and DrugBank screen results (Additional file 6).
We then performed drugs overrepresentation analysis of these 170 drugs. The background drug list used in this analysis includes all drugs targeting microbe proteins
homologs. Two analyses are conducted with two different drug classification systems,
including the anatomical therapeutic chemical classification system (ATC) and the Drugbank classification system. Surprisingly, both analyses demonstrate that the drugs used in
Diabetes are the statistically significantly overrepresented drugs categories (Tables 1 and 2).
Our predictions are supported by findings of which several anti-diabetic drugs can affect
microbiome compositions and may harbors anti-bacterial properties, such as Thiazolidinediones (TZDs) and metformin [60]. Even though no direct study and evidence shows that
the sulfonylureas inhibit pathogens, but one study shows indirect evidences of sulfonylureas
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Table 1 Hypergeometric test on drugs based on drug category information in Drugbank
Categories

p Value

Bonferroni
corrected p
value

B&H FDR
adjusted p
value

B&Y FDR
adjusted p
value

Nitric oxide synthase antagonists & inhibitors

0.00000

0.00012

0.00012

0.00082

Urea

0.00000

0.00029

0.00014

0.00094

Sulfonylureas

0.00004

0.01525

0.00508

0.03327

Oral hypoglycemics

0.00007

0.02843

0.00711

0.04652

Drugs used in diabetes

0.00018

0.06979

0.01204

0.07882

Sulfonylurea compounds

0.00019

0.07226

0.01204

0.07882

Stereoisomerism

0.00023

0.08839

0.01263

0.08264

Aldehyde reductase, antagonists & inhibitors

0.00041

0.16059

0.02007

0.13138

Enzyme inhibitors

0.00047

0.18206

0.02023

0.13239

Blood glucose lowering agents

0.00061

0.23983

0.02398

0.15696

Pyrazoles

0.00135

0.52458

0.04769

0.31211

Only the categories with Bonferroni corrected p value, B&H FDR adjusted p value, or B&Y FDR adjusted p-value lower than
0.05 are shown

Table 2 Hypergeometric test on ATC code information
Levels

p value

Bonferroni

B&H FDR
adjusted p
value

B&Y FDR
adjusted p
value

Description

A10BB

0.00002

0.00088

0.00088

0.00407

Sulfonylureas

A10B

0.00005

0.00298

0.00149

0.00689

Blood glucose lowering drugs, excl. insulins

A10

0.00013

0.00768

0.00256

0.01185

Drugs used in diabetes

A10BX

0.00087

0.04934

0.01234

0.05710

other blood glucose lowering drugs, excl.
insulins

A

0.00158

0.09024

0.01805

0.08355

Alimentary tract and metabolism

Only the categories with Bonferroni corrected p-value, B&H FDR adjusted p value, or B&Y FDR adjusted p value lower than
0.05 are shown

affecting the microbes involved in gut metabolism [61]. Besides, it is also worth noting that
the nitric oxide synthases antagonists & inhibitors are also enriched [62, 63].
Characterization of potential targets specific in pathogenic microbe proteins

We then identify targets that are homologs of pathogenic microbes’ proteins but not those
of commensal microbes’ proteins. The results can assist in discerning the potential directions in drug discovery. The scope of target identification is limited to the protein targets
collected in the Drugbank database. We selected 462 potential proteins. (Additional file 7).
Functional enrichment analysis was then performed on these selected targets with DAVID
[64, 65]. The background targets include all found homolog targets of microbes’ proteins
that are collected by sequence search against the Drugbank database. The results show that
proteins in periplasmic and cellular outer membrane are overrepresented (Table 3). The
statistically significant enriched functional annotations are signal proteins and transport
proteins.
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Table 3 Results from protein targets functional annotation analysis with DAVID
Categories

Bonferroni

B&H FDR adjusted p
value

B&Y FDR
adjusted p
value

Periplasm

0.00001

0.00001

0.00007

Signal peptide

0.00010

0.00010

0.00022

Topological domain: periplasmic

0.00045

0.00022

0.00100

GO:0009279 ~ Cell outer membrane

0.00011

0.00011

0.00104

Cell outer membrane

0.00028

0.00014

0.00133

GO:0030288 ~ Outer membrane-bounded
periplasmic space

0.00097

0.00048

0.00888

Transmembrane beta strand

0.00281

0.00094

0.01348

Signal

0.00555

0.00139

0.02669

Transport

0.01127

0.00226

0.05434

Only the categories with Bonferroni corrected p value, B&H FDR adjusted p value, or B&H FDR adjusted p value lower than
0.05 are shown

Discussion
Existing small-molecule microbiome drug discovery follows conventional one-drugone-gene-one-species paradigm [9], and focuses on preventing infection or fighting
against one microbe, barely considering the microbiome as an ecosystem. We believe
systems pharmacology approaches are necessary to identify small molecule drugs for
modulating the microbiome ecosystem. With the awareness of the complexity and diversity of microbiota, the reconstruction of microbiota networks is a critical step to study
the microbial community and to realize systems pharmacology, and it draws increasing interests [66]. Besides occurrence abundance correlation-based methods, exploring
microbes growth sources and chemical products is crucial to elucidate the mechanism
of interplay between microbes.
Our disease-centric microbe–microbe network, constructed based on literature
review and computational prediction, is still expected to improve and grow over time.
Currently, the label of each node is based on species level. This method introduces ambiguity when defining each species effect on health. For instance, E. coli, possess harmless
and commensal strains in the human gut, in the meantime, some strains are pathogenic
and even carcinogenic [49]. However, we believe that our network reflects the general
effects of microbiota on health, and are useful. Most of the abundant microbes, which we
include in our network, have been well studied regarding their metabolites and effects
on human health. Other microbes’ effect on health inferred with the SRWR method covered the information about how they affect human health by interplaying with abundant
microbes.
To incorporate host information and environmental factors into the construction of a
heterogeneous microbe–microbe interaction network can further enhance our understanding of the microbial community. Previous studies showed that environmental
factors are another crucial factors that determine the diversity and composition of the
microbial community [67]. Gut microbiota, as the most abundant microbial community, can be affected by personal daily diet and lifestyle [68]. For example, loss of sleep
could increase the ratio of Firmicutes to Bacteroidetes [69]. Microbial community is
believed to harbor discrete homeostasis states and transit between different states when
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experiencing environmental changes, at least for skin or vaginal microbiota [70, 71].
Thus, constructing a heterogeneous human–environment–microbiome network will be
an important direction for the future work.
The contemporary medical system undergoes an era of transition from traditional
population based diagnosis and treatment to a more precise personalized medicine.
Microbiota demonstrates high variability via developing different biogeographic signatures of human body sites [72, 73]. Small molecular drug discovery based on patient
particular microbiome signatures improves and assists in generating more efficient personalized diagnosis and treatment to cure disease. Our work provides the prime landscape of small molecule drug discovery by exploring the connection between microbe’s
genome and potential drugs.

Conclusion
In this paper, we systematically investigated the polypharmacological landscape of the
microbiome network. We found that a large number of proteins in pathogen microbes
are potential drug targets and inhibiting them may not significantly affect the human
host. We further showed that the potential drug targets that specifically exist in pathogenic microbes are periplasmic and cellular outer membrane proteins. We proposed
drugs for diabetes can be the lead compounds for development of microbiota-targeted
therapeutics. This study may open a new avenue for the small-molecule drug discovery
of microbiome for novel drug therapies.
Methods
Microbiome interaction network

Microbe species metabolite consumption and production information were manually
curated elsewhere [34]. 513 microbe species are included in this dataset. Distribution of
the number of metabolites each microbe consumes or produces, and distribution of the
number of microbes each metabolite associates with are investigated (Additional file 1).
We hypothesize that the final relationship between the two microbes is composed of a
negative relationship (competition) and a positive relationship (corporation). The negative extent, n
 egativeab, is calculated as the Jaccard similarity of metabolite consumption
profile between microbe a and microbe b.

Negativeab =

|Ca ∩ Cb |
|Ca | + |Cb | − |Ca ∩ Cb |

Ca and Cb are the consumption profile of microbe a and microbe b. 233 metabolites are
investigated and are consumed by at least one microbe species. The positive extent,
positiveab, is calculated as the Jaccard similarity of microbiome a’s metabolites consumption profile to microbiome b’s production profile.
Positiveab =

|Ca ∩ Pb |
|Ca | + |Pb | − |Ca ∩ Pb |

Ca and Pb are the consumption profile of microbe a and production profile of microbe b.
The final microbiome interaction network is a directed graph.
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Signed Random Walk with Restart (SRWR)

The dynamicity of microbiome interaction network with selected 513 microbial species is simulated using Signed Random Walk with Restart algorithm [37]. To predict
the label (pathogenic or commensal) of a unannotated microbe species, it is initialized as a start node. For each run, initial score of 1.0 is assigned to the start node with
an unknown sign, and then this score is distributed out to the neighboring nodes via
edges in the network as the walk goes with random probability. Positive edge would
increase the positive ranking score of the neighboring node with the balance attenuation probability of β = 0.5, and the negative edge would increase the negative ranking score of the neighboring node with the probability of γ = 0.5. When the walk is
complete, positive scores from known commensal species, and negative scores from
known pathogenic species are summed up to predict the label for the unknown start
node (Additional files 2, 3, and 4).
Microbe proteins druggability survey

Protein sequences of microbes are downloaded from Human Microbiome Projects
(HMP) [2, 51]. Druggable target sequences are downloaded from Drugbank (www.
drugbank.ca) and ChEMBL websites (www.ebi.ac.uk/chembl) [52, 53]. They are saved
as fasta format and reformatted to be a Blast database using PSI-Blast tools [54–56].
Microbe protein sequences are searched against each target sequence database to find
their homologs. Biopython package is used to perform sequence comparison using
PSI-Blast [54–56]. All sequence search results with e-value lower than 10e-4 are saved
for further analysis. Scripts used for analysis are available in https://github.com/qiaol
iuhub/drug_target_analysis_on_microbiome.
Potential drugs screening
Drugbank

The drug-target interaction database is downloaded from Drugbank (www.drugbank.
ca) [52]. By using the homolog targets from the sequence search, we collect the drugs
that potentially target microbe proteins for each microbe. All drugs that potentially
target pathogenic microbes are gathered into a candidate list, then parts of the drugs
in the list are excluded if they can potentially target commensal microbes. 589 drugs
in the candidate list are left after screening.
STITCH

STITCH database is downloaded from http://stitch.embl.de [74]. STITCH database
has grouped drug-target interactions based on microbe species. These drug-target
interactions are also classified into different types, such as inhibition, activation, or
catalysis. We focus on two interaction types: inhibition and activation. Our primary
purpose is to screen for FDA approved or investigational drugs, so we excluded nondrugs compounds. We utilize the STITCH drug ID information, which is also the
same with PubChem compound ID, to retrieve the pharmaceutical function information from the PubChem database by using PUG REST API and E-utilities tools [75].
We perform the following screen: (1) Compounds that activate targets in pathogenic
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microbes but not activate targets in commensal microbes (134 drugs). (2) Compounds
that activate targets in pathogenic microbes but not inhibit targets in commensal
microbes (431 drugs). (3) Compounds that inhibit targets in pathogenic microbes but
not inhibit targets in commensal microbes (185 drugs). (4) Compounds that inhibit
targets in pathogenic microbes but not activate targets in commensal microbes (1325
drugs) (Additional file 8).
The intersection of Drugbank screening and STITCH screening result

The InChIKey information of all drugs found in Drugbank screening is retrieved from
Drugbank full database XML file. The InChIKey information of all drugs found in
STITCH screening is collected from the Pubchem website using PUG REST API and
E-utilities tools. The intersection of these two drugs InChIKey set is found for later
analysis.
Overrepresentation analysis
Drug overrepresentation analysis

All selected drugs’ ATC code and Drugbank classification information are accumulated
from Drugbank full database XML file. These two classification systems have hierarchical structures, and all categories in all levels are included. A hypergeometric test is
performed on the Drugbank screened 589 drugs list. The Bonferroni correction, Benjamini & Hochberg’sHochberg’s FDR adjustment, and Benjamini & Yekutieli’sYekutieli’s
FDR adjustment methods are used to adjust the p-values of these multiple comparisons. ~ 3700 drugs, which are found to target at least one microbe protein homolog, are
used as background drugs list (Additional file 9).
Protein targets functional enrichment analysis

462 potential protein targets are filtered out using the Drugbank target sequences
database and saved with their UniProt accession numbers. Potential targets functional
enrichment analysis is conducted with the database for annotation, visualization,
and integrated discovery (DAVID) [64, 65]. The list of 462 potential targets’ UniProt
accession numbers was uploaded to DAVID as a test gene set. Background gene set
includes ~ 1700 microbe protein homologs found in Drugbank (Additional file 10).
Term definition

Microbiome: Collection of all microbes (bacteria, fungi, and viruses) that are naturally live in the human body.
Pathogen microbe: A microbe that causes diseases.
Commensal microbe: A microbe that has a neural relationship (neither benefit nor
harm) with the host.
Competition: Microbes compete with each other for survival.
Mutualism: Microbes are mutually dependent.
Commensalism: Microbes neither benefit nor harm each other.
Parasitism: Microbes live on other microbes.
Amenalism: A microbe inhibits another microbe, but itself is not affected.
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Systems pharmacology: A drug discovery paradigm that aims to modulate multiple
microbe targets in the microbiome-microbiome interaction network.
Polypharmacology: A compound can inhibit or activate multiple targets simultaneously.
Drug repurposing: Use of existing drugs for different clinical indications from the
original one.

Abbreviations
T1D	Type 1 diabetes
T2D	Type 2 diabetes
IBD	Inflammatory bowel disease
RA	Rheumatoid arthritis
SRWR	Signed Random Walk with Restart
SR	Spectral ranking
MPR	Modified PageRank
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